SCHEMBL488492

SCHEMBL488492

CC(Oc1nc(-c2ccc(NS(=O)(=O)CCNCC3CC3)cc2)cnc1N)c1c(F)ccc(F)c1Cl

nearest known ligand 0.46

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
MAP4K3 Q8IVH8 1/20 0.46
MET P08581 14/20 0.44
CHEK2 O96017 1/20 0.44
PIK3CD O00329 1/20 0.34
PIK3CA P42336 1/20 0.34
PIK3CB P42338 1/20 0.34
PIK3CG P48736 1/20 0.34
SGK1 O00141 3/20 0.33
INSR P06213 1/20 0.33
NPM1 P06748 1/20 0.33
ALK Q9UM73 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30453976 1.00 MAP4K3 (0.46) MAP4K3METCHEK2PIK3CDPIK3CA
SCHEMBL488303 0.89 MAP4K3 (0.47) MAP4K3METCHEK2SGK1INSR
SCHEMBL30454515 0.89 MAP4K3 (0.47) MAP4K3METCHEK2SGK1INSR
SCHEMBL487733 0.85 MET (0.50) MAP4K3METCHEK2ALK
SCHEMBL30453377 0.85 MET (0.50) MAP4K3METCHEK2ALK
SCHEMBL487823 0.85 CSF1R (0.37) MAP4K3METCHEK2PIK3CDPIK3CA
SCHEMBL30452931 0.85 CSF1R (0.37) MAP4K3METCHEK2PIK3CDPIK3CA
SCHEMBL488524 0.84 MET (0.45) MAP4K3METCHEK2SGK1ALK
SCHEMBL30453613 0.84 MET (0.45) MAP4K3METCHEK2SGK1ALK
SCHEMBL488174 0.83 MET (0.47) MAP4K3METCHEK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106197-B2 Aminoheteroaryl compounds as protein kinase inhibitors PFIZER INC. (US) 2012-01-31 US disclosed
US-8106197-B2 Aminoheteroaryl compounds as protein kinase inhibitors PFIZER INC. (US) 2012-01-31 US disclosed
US-8106197-B2 Aminoheteroaryl compounds as protein kinase inhibitors PFIZER INC. (US) 2012-01-31 US disclosed
US-7230098-B2 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer SUGEN, INC. (US) 2007-06-12 US disclosed
US-7230098-B2 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer SUGEN, INC. (US) 2007-06-12 US disclosed
US-20070072874-A1 Aminoheteroaryl compounds as protein kinase inhibitors SUGEN, INC. 2007-03-29 US disclosed
US-20070072874-A1 Aminoheteroaryl compounds as protein kinase inhibitors SUGEN, INC. 2007-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070072874-A1 Aminoheteroaryl compounds as protein kinase inhibitors MET, MAP4K1, MAP4K2 MAP4K3 8/4885MET 1/4885CHEK2 296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.